London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
keithbfk and bignose i completely agree with you.i hope we are all wrong but as i posted before they seem to be flailing around without reel direction.as you say bignose yooya would have given them an online retailing position and this was why i was feeling quite positive about it as i hoped it would give them a fairly immediate source of revenue albeit small to start with which would have helped with the cash position. they would have needed to source products but that seemed to be part of the plan.as you say its not at all clear what they have in mind here and it does smack of chasing the next big thing.there are i gather a great many cbd producers so I'm feeling bit of deja vu as its reminiscent for me of the dotcom bubble and the plethora(sorry) of would be internet service providers most of whom disappeared without trace.hope I'm wrong but i entirely agree that even if they get into a potentially profitable niche do they have the abilities and competencies to bring it off?glad no announcement today so presumably this means the CLNs are still on track and I'm hopeful that abony will still be put on the board and that Costanzo will take some interest as an investor.costanzo worked for uber and is probably used to seeing results delivered so lets hope for a culture shock for jamie and a shake up of the applecart.does this new approach tie in with the "already identified and significantly diligenced (arghh!) acquisition and investment opportunities" already referred to in the circular?perhaps not as this seems a different area of operation but we need more detail.
rooster not sure if this is any help but have you tried contacting HSBC.i think they have specialist hong kong dealing services.not sure how helpful they would be for a one off and in certificated form but they may be able to point you in the right direction
I have 1.8 million shares in rpg from the original investment in plethora, im about to retire , these were supposed to prop up my pension but there worth a fraction of cost , I hold these in certificate form at home , any ideas how I can sell them now as HL don't trade in hk ?thanks in advance
Big nose, totally agree. They seem to be wondering around searching for something without any knowledge or understanding what it is. Another ‘money fountain’ DBC in the offing.
Doesn’t anyone find it strange that Yooya were an e-commerce company and as such RPG would need further investment in CBD companies, yet now we are told whilst in discussions with Yooya, they were presented with a more exciting opportunity involving the hemp sector in China, with a particular focus on hemp CBD infused products. But isn’t that what they would need to be getting involved with anyway to enable them to use Yooya ?
These last announcement are certainly full of BS and many twists and turns and the usual vagueness. Do they actually know what they are doing ? This time, there is not one person, including Dr Mike, who has any knowledge on the subject, yet they are capable of making these decisions.........it seems to me that they have seen business articles on CBD with projections and are just trying to jump on the wagon full of “we want a piece of that” although we know nothing about it. Well just BS and hope this one pays off.....Will this be another DBC ?
My post regarding JG update is still there.....at 1508 on Tuesday 16th.........
thanks for putting my mind at rest Bothwell.didnt think i had imagined it .seemed a perfectly innocuous post to me which is why i mentioned it.
I have had a post deleted. All I asked if anyone had been in contact with JM or JG. Also JM had also been positive regarding Fortacin & RP when I contacted him.
agree bignose it does look al little suspicious to me.yes trading pattern has been a little od.i think it was wednesday when there were over 50trades (quite a lot for rp on a low volume day which it was)and almost all were sells for 10000 shares.i wonder if we will get a further announcement today after close.i rather hope not as it probably won't be good news.we shall see
What I find of interest is the fact they suddenly have an alternative, but concrete solution, yet no information to shareholders as required until now. That's highly impossible. They must have been in discussions with another party many weeks ago, yet nothing until now. Makes one wonder why ? Are they once again being over zealous to try and keep the SP up in preparation for the Dilution, it surely wont look good if the SP drops further before the EGM vote. Interesting that although volumes are low, there are many sells around the 10k share mark which could indicate that there is some manipulation going on. Granted there are a few larger sells, but why so many 10k's one after another. Makes no sense unless there are many Chinese who have invested in 10 of shares.....LOL.
No news on Orient and no news on Recordati....... why ?
i know i have been displaying symptoms of anomic aphasia but is my mind playing more tricks.i could have sworn there was a post on here from(i think) bunion which has now gone
so re fortacin and china it looks as though the earliest we can expect the $4m is some time in Q1 2020 and thats assuming the quoted time scale is not overly optimistic and that we encounter no problems or setbacks in the process.makes the refinancing even more urgent imo.im not clear about the long term time scale here but it still sounds some way away.re the FDA i have no idea whether the projected timescale is overly optimistic or not but it wouldn't surprise me if it is.having had experience of the FDA process recently on another share it would certainly not surprise me if there were delays and difficulties so i can well imagine that approval (assuming it can be obtained) maybe some considerable way off.on a positive note as i posted yesterday there may be some interest in regent generated by the knowledge that the process is advancing next year but hard to see any real interest arising before actual approval.sorrry if this is all very negative and would welcome any positive countervailing views
just checked and the proposal the Abony join the board was contained in the Yooya acquisition announcement so presumably this will not now happen.hope I'm wrong as new blood needed imo
having had a chance to look at the announcement in detail i have to confess to feeling extremely deflated.of course we all knew that it was theoretically possible for the deal not to go through but one thing i always felt mellon was good at was getting this type of deal through so I'm very surprised it has been called off.obviously its better to pull out of a proposed deal if its not on the right terms but I'm now left with the strong impression of a company faced with a failing product desperately flailing around for another direction to take to save itself from extinction.can i take any comfort from the rest of the announcement?well not much.i just hope the reference to a chinese alternative is not some calculated flannel designed to soften the blow which will be quietly forgotten or else also come to nothing in a few months time.its not at all clear what the opportunity is but certainly there does appear to be huge competition in the cbd production market.i suppose it all depends what the target is.at least the reference to less dilution is ,as has been said,potentially welcome and it will be interesting to see if there is any market reaction tomorrow.the initial anouncement caused little reaction so probably the same will happen now. on a point of detail will this affect the CLN refinancing?although the original announcementt did not put the acquisition of Yooya as a reason for the CLN scheme the recent circular clearly included it a one of the reasons so perhaps they will have to postpone the e.g.m and reissue the circular.i sincerely hope not. i assume the proposed investors in the CLNs (abony etc ) will still want to go ahead but again some slight concern there. further comments re FDA and china to follow
That's "alluded", although I'm sure they would love to elude a requirement for two pivotal studies.
That's a bit harsh- RP is equally inconsistent with inaccurate information.
I see that the famous Gibson time dilation effect is still in effect. Good show if the validation study will complete early, but since there is no fixed timeline for a full COA qualification package review (and with the current street estimate being 6-10 months), a Q1 2020 start for pivotal study work is pretty nigh impossible. And let's not dismiss the risk around submitting what is no more than a pilot study for an otherwise untested endpoint.
Assuming there's not a typo in the dates, you are looking at the shortest Phase III and NDA submission in history:again, pretty nigh impossible. RP have eluded to a single pivotal study, but outside of cancer and high need conditions, the FDA requires two studies (and historically, this has been the case for the few PE pivotal studies submitted in the last decade). And when are they planning to address the combination product rule question?
China timeline is close enough - 60 day IND review if nothing amiss with the submission, but there's no allowance for a pre-IND submission meeting, so add another 30-60 days and call it sometime late Q1 2020 until the NMPA response. Still no mention of the Taiwan FDA bridging study requirements.
As for the possible involvement in indigenous hemp/CBD production, hard to evaluate without more detail. Hemp production and CBD extraction are strictly regulated but there appears to be an increasing number of licences granted to Chinese companies. Hemp seek, oil and CBD are legal for use in cosmetics (but not ingestion), and not for medical use
The Chinese require animal testing for cosmetic approval (leading to a complex importation route for foreign cosmetics, although readily navigated by the majors) and no medical or wellness claims can be made that might assist with product differentiation. Chinese cosmetics do not meet EU or US conditions, so not possible to export finished product. So, all down to hemp/CBD export from China into increasingly competitive/self-sufficient markets?
https://www.cannabis-mag.com/2019/04/17/the-booming-cannabidiol-market-in-China/ looks like the cbd position in china is quite complex.further thoughts in due course/
Unfortunately, ‘Mr Know It All’ is invariably able to respond quickly because RPG are so inconsistent with accurate information that they play into his hands. It is easy to haul this company over any number of coals given their complete ineptitude.
Firstly I'd like to ask. what about Orient and HK/Macau. surely those two launches are much further along than either the FDA or the China syndrome or even a new acquisition ?
The start of the phase 2 was delayed from July until Dec, but if that delay is anything to go by. (JG informed the market and later me by email after I noticed the FDA gov website was indicating still no recruiting in August, that all was on schedule). An utter BS response with no knowledge of what was going on since it was then delayed till Dec.
I'm not sure about the new route. My understanding was that at least Yooya would not just be limiting itself to China, whereas this update indicates the new company will be in China, yet all my research so far has indicated that although China is one of the worlds largest industrial producers of Hemp, they still have not approved CBD for medical use. Please correct me if I am wrong. Unless they are only looking to China to supply Hemp ?
I assume it wont be too long before Mr "know it all" responds to the FDA update. Anyone want to have guess as to how long before he posts again with his narcistic views ? My guess is within the next hour or 2.... ;-)
Latest update today:
Have I read it correctly?
US update looks as though it is now 6 months behind schedule compared to July 2018 update or have I misread?
I am pleased though that they had a second plan on the table after the yooya deal didn't work out.
At least there is some effort occuring there to begin the process of adding to the RPG portfolio.
This announcement looks more promising and highlights less dilution to shareholders. There is enough there to add some interest through the next quarter or rather late 2019 and into new year. Fingers crossed in ignites greater opimism in Hong Kong
keith/bignose agree with all you say today.very disappointing to see all the impetus which we hoped recordati would bring to fortacin evaporating.unless sales are better than we expect,which i doubt,its hard not to see recordati losing interest.so fortacin wise i suspect we are going to have to wait for progress with FDA application before there is anything positive to say.china may help eventually but not holding my breath.on a positive note assuming the FDA application is progressed as proposed(unfortunately give their history thats quite a big assumption re regent),by the start of next year it will not seem quite so far away so may generate some interest as 2020 progresses.the main reason ,however, that i am encouraged in the meantime by the possible change in direction,is not that i think CBD is necessarily going to be the next big thing(it may be but it could also be the next tulip bubble),but rather that if it all goes ahead there will be a widening of the core investor base.until now its really only been mellon as the sole significant investor.with abony on the board i really do expect gibson s performance to come under much greater scrutiny.just going on the anecdotal evidence of the news re EMMAC and its spate of acquisitions over thelast few months i do not get the feeling that antonio costanzo is someone who lets the grass grow under his feet.if he and the others do invest then i expect rapid expansion in the CBD area and if gibson is not able to deliver this he will go.my comments about his loan being converted in effect into a share entitlement to assist in his departure if he fails to deliver is of course just speculation but i do sense a sea change here imo.
Bignose, again totally agree. Initially when Recordati, a big company, decided to market Fortacin I was excited and thought things were really on the move. It is equally frustrating and baffling that they then proceeded to do little to promote the product. I remember looking at their website which provides details of which products are available in the different countries and they had missed Fortacin off the list in a couple of areas where they had stated that it was available. Ugh....
You have certainly got that right "flying by the seat of their pants". RPG/Recordarti evidently have not done one piece of market research and taken it for granted that 1 in 4 male sufferers = lots of sales. How is it they had not even heard about the 2006 German study made on exactly the subject. Did they all deliberately ignore this ? It must have been discussed and readily available in the right circles which RPG and Recordati would have been involved in. If known, they had plenty of time to make preparations before launches. They surely would then not be making such statements as "disappointing", but instead "as expected". A disasters that could have been prepared and actioned against if managed by true professionals.